As of May 23, 2025, PTC Therapeutics Inc (PTCT) reports a ROA (Return on Assets) of -21.31%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of PTC Therapeutics Inc's ROA (Return on Assets)
Over recent years, PTC Therapeutics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -21.31% |
| 2023-12-31 | -33.05% |
| 2022-12-31 | -32.77% |
| 2021-12-31 | -27.03% |
| 2020-12-31 | -19.84% |
This slight downward trend highlights how PTC Therapeutics Inc manages its efficiency in using assets to generate earnings over time.
Comparing PTC Therapeutics Inc's ROA (Return on Assets) to Peers
To better understand PTC Therapeutics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| PTC Therapeutics Inc (PTCT) | -21.31% |
| Agios Pharmaceuticals Inc (AGIO) | 40.51% |
| ACADIA Pharmaceuticals Inc (ACAD) | 19.07% |
| MiMedx Group Inc (MDXG) | 16.07% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| China Biologic Products Holdings Inc (CBPO) | 6.74% |
Compared to its competitors, PTC Therapeutics Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.